摘要
目的探讨阿替普酶静脉溶栓治疗心源性及非心源性脑梗死效果。方法选取该院2016年1月—2017年12月阿替普酶静脉溶栓治疗的脑梗死患者60例并根据脑梗死类型分为心源性脑梗死组和非心源性脑梗死组。比较两组治疗的总有效率,平均住院时间,治疗前后患者NHISS评分、m RS评分、改良RANKIN量表评分,药物不良反应率。结果观察组治疗总有效率93.33%高于对照组的66.67%(χ~2=13.520 0,P<0.05);观察组平均住院时间(7.11±1.13)d短于对照组的(8.42±2.13)d(t=8.155 6,P<0.05);治疗前两组NHISS评分、m RS评分、改良RANKIN量表评分无统计学意义(P>0.05);治疗后观察组NHISS评分、m RS评分、改良RANKIN量表评分优于对照组(P<0.05)。观察组药物不良反应率10.00%低于对照组的33.33%(χ~2=8.2114,P<0.05)。结论阿替普酶静脉溶栓治疗非心源性脑梗死效果优于心源性脑梗死的效果,可更好恢复神经功能,改善生活质量,且不良反应更少,值得推广应用。
Objective This paper tries to investigate the efficacy of intravenous infusion of aheplase in the treatment of cardiogenic and noncardiogenic cerebral infarction. Methods 60 cases of cerebral infarction with aheplase thrombolytic therapy from Janury 2016 to December 2017 in the hospital were selected and classified into cerebral infarction group and non-cardiac cerebral infarction group according to cerebral infarction type. The total effective rate, average length of stay, and patients＇ NHISS score, mRS score, modified RANKIN scale score, and drug adverse reaction rate before and after treatment were compared between the two groups. Results The total effective rate of treatment in the observa- tion group was 93.33% higher than that of the control group 66.67%（X2=13.520 0, P〈0.05）; the average length of stay in the observation group was （7.11±1.13）d shorter than the control group （8.42±2.13）d （t=8.155 6, P〈0.05）. Before treatment, there were no significant differences in NHISS score, mRS score, and modified RANKIN scale between the two groups （P〉0.05）. After treatment, NHISS score, mRS score, and modified RANKIN score in the observation group were better than those in the control group （P〈0.05）. The rate of adverse drug reactions in the observation group was 10.00% lower than that of the control group 33.33%（X2=8.211 4,P〈0.05）. Conclusion The effect of intravenous infu- sion of aheplase on non-cardiogenic cerebral infarction is superior to that of cardiogenic cerebral infarction. It can re- store neurological function, improve quality of life, and fewer adverse reactions. It is worthy of popularization and appli- cation.
作者
汤群英
于建刚
徐红
TANG Qun-ying;YU Jian-gang;XU Hong(Department of Neurology,Jingjiang People＇s Hospital,Jingjiang,Jiangsu Province,214500 China)
出处
《系统医学》
2018年第9期87-89,共3页
Systems Medicine
关键词
阿替普酶静脉溶栓
脑梗死
效果
Aheplase intravenous thrombolysis
Cerebral infarction
Effect
